References of "Dubois, C"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study
Van Obbergh, F; Knoops, L; Devos, T et al

in Clinical Biochemistry (in press)

This retrospectivemulticenter study in patientswith chronic myeloid leukemia in chronic phasewas undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice ... [more ▼]

This retrospectivemulticenter study in patientswith chronic myeloid leukemia in chronic phasewas undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one patients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a fixed 400mg daily dose. A significant inverse relationship of imatinib concentration with the patients' weight was observed (Pearson's test: p=0.02,R2=0.1). More interestingly, patientswith poor response (switched to another tyrosine kinase inhibitor because of imatinib failure, or because of disease progression after an initial response) displayed a significantly lower mean imatinib concentration as compared to patients maintained on imatinib (822 ng/mL vs 1099 ng/mL; Student's t-test, p=0.04). Failure or disease progression occurred more often in patients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p = 0.02, logrank test). No correlation could be established with other biological or clinical parameter, including complete cytogenic response and majormolecular response. In conclusion: in patients treatedwith imatinib at a fixed daily dose of 400 mg, imatinib plasma concentrations decreased with increasing body weight and were lower in patients switched to another tyrosine kinase inhibitor due to imatinib failure. Systematic determination of imatinib plasma trough levels should be encouraged in such patients. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailEvolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, D. et al

in Revue du Rhumatisme (2011, December), 78(Suppl. 5), 43-44

Detailed reference viewed: 52 (9 ULg)
Full Text
Peer Reviewed
See detailX-FEM explicit dynamics for constant strain elements to alleviate mesh constraints on internal or external boundaries
Rozycki, P.; Moes, N.; Béchet, Eric ULg et al

in Computer Methods in Applied Mechanics & Engineering (2008), 197(5), 349-363

This paper deals with the use of the extended Finite Element Method (X-FEM) for rapid dynamic problems. To solve the equations of motion, a common technique is the explicit direct integration with a ... [more ▼]

This paper deals with the use of the extended Finite Element Method (X-FEM) for rapid dynamic problems. To solve the equations of motion, a common technique is the explicit direct integration with a Newmark scheme. Since this temporal scheme is only conditionally stable, the critical time step must be determined. It is generally induced by mesh constraints. The idea of the paper is to weaken constraints on mesh generation algorithms so that the critical time step is as large as possible. Using the X-FEM one allows a non-conformity between mesh and discontinuities such as cracks, holes or interfaces. In a first part, we present a summary about direct integration schemes and about the eXtended Finite Element Method. Then, we focus on the theoretical description of a ID X-FEM finite element and its generalization to 2D and 3D finite elements. Then, dynamic numerical simulations are shown. They concern structures under impact with holes or external boundaries not exactly matched by the mesh. Comparisons are made with numerical results coming from the ABAQUS software. It shows that developments are satisfactory. We conclude with some outlooks concerning this work. (c) 2007 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 121 (5 ULg)